Needham & Company LLC Issues Pessimistic Forecast for Blueprint Medicines (NASDAQ:BPMC) Stock Price
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $133.00 to $130.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 46.93% […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lowered by analysts at Needham & Company LLC from $133.00 to $130.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 46.93% […]
